BREA, Calif., Nov. 10, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") today announced that it has priced an offering (the "Offering") of $430 million in aggregate principal amount of its 6.250% Senior Notes due 2033 (the "Notes") at the issue price of 99.482% of their principal amount.

The Offering is expected to close on or about November 24, 2026, subject to the satisfaction of customary closing conditions. Envista intends to use the net proceeds from the Offering (i) to repay the outstanding obligations under its U.S. dollar term loan A facility and pay the fees, premiums, expenses and costs incurred in connection with the foregoing and (ii) for general corporate purposes.

J.P. Morgan Securities LLC, BofA Securities, Inc. and Wells Fargo Securities, LLC are acting as active bookrunners for the Offering.

The Offering is being made pursuant to an effective shelf registration statement on Form S-3ASR (File No. 333-299917) filed by Envista with the U.S. Securities and Exchange Commission (the "SEC") under the Securities Act of 1933, as amended. The Offering will be made by means of a prospectus supplement and accompanying prospectus only. A copy of the preliminary prospectus supplement and accompanying prospectus are available on the SEC's website at www.sec.gov. Alternatively, any underwriter or any dealer participating in the Offering will arrange to send you the preliminary prospectus supplement (or, if available, the prospectus supplement) and the accompanying prospectus if you request them by contacting: J.P. Morgan Securities LLC (collect) at 1-212-834-4533, BofA Securities, Inc. (toll-free) at 1-800-294-1322 or Wells Fargo Securities, LLC (toll-free) at 1-800-645-3751.

This press release shall not constitute an offer to sell or a solicitation of an offer to purchase the Notes or any other securities. No offer, solicitation or sale will be made in any jurisdiction in which such an offer, solicitation or sale would be unlawful.

About Envista Holdings Corporation

Envista Holdings Corporation (NYSE: NVST) is a global leader in the dental industry, uniting more than 30 trusted brands—including DEXIS, Kerr, Nobel Biocare, and Ormco—under one mission: partnering with dental professionals to improve patients' lives. With a heritage of category-defining innovation, our brands have shaped modern dentistry: Nobel Biocare introduced the first modern dental implant, Ormco is a pioneer in both traditional and digital orthodontics, DEXIS has long been at the forefront of 2D, 3D and intraoral imaging, and Kerr has supported clinicians for over 135 years. Our high-performing culture is underpinned by our CIRCLe Values and the Envista Business System. Guided by these, we deliver a comprehensive portfolio of technologies, consumables, and services that empower clinicians to provide confident, efficient care—today and for the future.

Forward-Looking Statements

Certain statements in this press release are "forward-looking" statements within the meaning of the federal securities laws. The forward-looking statements contained in this press release, concerning, among other things, Envista's issuance of the Notes and the use of proceeds therefrom, involve risks and uncertainties, and are subject to change based on various important factors and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, market risks and uncertainties and the satisfaction of customary closing conditions for an offering of securities, the conditions in the U.S. and global economy, the impact of inflation and increasing interest rates, slower economic growth or recession, international economic, political, legal, compliance and business factors, the markets served by us and the financial markets, the impact of our debt obligations on our operations and liquidity, developments and uncertainties in trade policies and regulations including tariffs or other impositions on imported goods, contractions or growth rates and cyclicality of markets we serve, risks relating to product manufacturing, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole or limited sources of supply, disruptions relating to war (including supply chain disruptions), terrorism, climate change, widespread protests and civil unrest, man-made and natural disasters, public health issues and other events, security breaches or other disruptions of our information technology systems or violations of data privacy laws, security breaches or other disruptions affecting our external information technology contractors, vendors or other service providers, our growing use of artificial intelligence systems to automate processes and analyze data, fluctuations in inventory of our distributors and customers, loss of a key distributor, our relationships with and the performance of our channel partners, competition, our ability to develop and successfully market new products and services, our ability to attract, develop and retain our key personnel, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, penalties associated with any off-label marketing of our products, modifications to our products that require new marketing clearances or authorizations, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated benefits of such acquisitions, contingent liabilities relating to acquisitions, investments and divestitures, our ability to adequately protect our intellectual property, the impact of our restructuring activities on our ability to grow, risks relating to impairment charges for our goodwill and intangible assets, changes in accounting standards and subjective assumptions, estimates and judgment by management, currency exchange rates, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, risks relating to product, service or software defects, the impact of regulation on demand for our products and services, and labor matters. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our Annual Report on Form 10-K for fiscal year 2025 and our Quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date of this press release and except to the extent required by applicable law, we do not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

Contact

Jim Gustafson
Vice President, Investor Relations
Envista Holdings Corporation
200 S. Kraemer Blvd., Building E
Brea, CA 92821
Telephone: (424) 350-5259
ir@envistaco.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/envista-announces-pricing-of-430-million-of-senior-notes-302935616.html

SOURCE Envista Holdings Corporation